The quarter beat a fairly constructive market bar. Adjusted diluted EPS was $0.89 versus published consensus of about $0.83, while revenue was $265.8 million versus roughly $262.3 million expected — a $0.06 EPS and $3.5 million revenue beat. The result also exceeded the company’s prior Q2 guidance for revenue of $259–264 million, Adjusted EBITDA of $58–62 million, and adjusted EPS of $0.81–0.86. (Financial Guidance)
| Metric | Q2 2026 | Q2 2025 | Expectation / prior guide |
|---|---|---|---|
| Revenue | $265.8M | $241.0M | Consensus ~$262.3M |
| Organic revenue growth | 9.3% | — | Prior guide: 6%–8% |
| Adjusted EBITDA | $60.7M | $52.2M | Prior guide: $58M–$62M |
| Adjusted EBITDA margin | 22.8% | 21.6% | — |
| Adjusted diluted EPS | $0.89 | $0.76 | Consensus ~$0.83; prior guide: $0.81–$0.86 |
| Operating cash flow | $64.9M | $15.1M | — |
The most important improvement was underlying demand, not currency or acquisition accounting. Reported revenue rose 10.3%, but 9.3% was organic; currency contributed only 1.0%, and acquisitions contributed no year-over-year growth in the quarter. That is materially better than the 6%–8% organic-growth target previously set for Q2 and represents Novanta’s strongest organic-growth quarter since Q1 2023. (Organic Revenue Growth; Financial Guidance)
The beat was broad, but not uniform across segments. Automation Enabling Technologies revenue increased to $136.2 million from $121.7 million, with adjusted gross margin expanding to 53.4% from 48.9%. Medical Solutions revenue grew more modestly to $129.6 million from $119.4 million, while adjusted gross margin fell to 41.1% from 44.0%. The overall margin improvement therefore came chiefly from automation and operating leverage, not a clean improvement across the portfolio. (Revenue by Reportable Segment; Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment)
The guidance reset is the larger positive change, though Riverpoint is doing much of the work. Full-year revenue guidance rose from $1.040–$1.055 billion to $1.130–$1.140 billion; Adjusted EBITDA from $245–$250 million to $273–$278 million; and adjusted EPS from $3.50–$3.65 to $3.68–$3.74. Q3 guidance of $300–$304 million revenue and $0.95–$1.00 adjusted EPS is also above the published pre-release estimates of about $263.1 million and $0.94, respectively. However, the new outlook incorporates the recently closed Riverpoint Medical acquisition, so the uplift is not purely a higher stand-alone forecast. (Financial Guidance)
Cash generation and balance-sheet flexibility strengthen the read. Operating cash flow surged to $64.9 million and free cash flow to $57.5 million, while reported net debt became negative $479.9 million, or net cash, at quarter-end. The offset is that the private placement raised $288.5 million and diluted weighted-average shares to 41.2 million from 36.1 million a year earlier. (Cash Flow statement; Net Debt; Income Statement)
Net read: a genuine beat with a meaningful outlook upgrade. The quarter surpassed both consensus and the company’s own targets, and the 9.3% organic growth rate makes the acceleration credible. The main qualification is that the full-year step-up now depends partly on integrating Riverpoint and capturing its promised accretion, while Medical Solutions’ margin decline remains an area to monitor.
Read the original 8-K on SEC EDGAR ↗